Friday 6 November 2026 Export HALO’s income statement to Excel — free account

Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.

Revenue: +39.2%
EPS: +45.6%
Free cash flow: −58.6%
Total debt: +115.1%

Quarter to September 2026, against a year earlier

103.93 19.03 −15.48%

Follow HALO

Alert me

Market cap: $14.0B
P/E: 29.5×
Fwd P/E: 17.9×
Dividend yield: —
F-score: 5/9
Altman Z: 3.46
Beneish M: −2.59
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Halozyme Therapeutics, Inc. (HALO) revenue by segment, product and region

	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q1 FY2023
Royalties	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Proprietary product sales	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Bulk rHuPH20 sales	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Sales-based milestones	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Device partnered product sales	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Event-based development and regulatory milestones and other fees	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Upfront license and target nomination fees	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Device licensing and development revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Research and Development Services	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
ENHANZE drug product [Member]	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenues under collaborative agreements	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Product sales, net	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Halozyme Therapeutics, Inc. (HALO) revenue by segment, product and region

Stockrow Weekly